Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases
The association between hyperuricemia and cardiovascular diseases has been studied for many years. Research has shown a link between high uric acid levels and increased risk of including coronary artery disease hypertension and other cardiovascular conditions. Urate-lowering therapy, particularly wi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-03-01
|
| Series: | Clinical Medicine Insights: Cardiology |
| Online Access: | https://doi.org/10.1177/11795468241239542 |
| _version_ | 1827309563859173376 |
|---|---|
| author | Franklin Sosa Mohammed Shaban Jose Lopez Gustavo J. Duarte Swati Jain Asma Khizar Timothy Vittorio Rishabh Mishra Miguel Rodriguez Guerra |
| author_facet | Franklin Sosa Mohammed Shaban Jose Lopez Gustavo J. Duarte Swati Jain Asma Khizar Timothy Vittorio Rishabh Mishra Miguel Rodriguez Guerra |
| author_sort | Franklin Sosa |
| collection | DOAJ |
| description | The association between hyperuricemia and cardiovascular diseases has been studied for many years. Research has shown a link between high uric acid levels and increased risk of including coronary artery disease hypertension and other cardiovascular conditions. Urate-lowering therapy, particularly with xanthine oxidase inhibitors like allopurinol, has shown promising results in reducing blood pressure in individuals with hyperuricemia and hypertension. Clinical trials and studies have demonstrated significant reductions in both systolic and diastolic blood pressure with urate-lowering treatment. Urate-lowering treatment has shown a favorable effect on reducing systolic blood pressure and major adverse cardiovascular events in patients with previous cardiovascular disease. In terms of cardiovascular safety, clinical trials have indicated that xanthine oxidase inhibitors such as febuxostat are non-inferior to allopurinol and do not increase the risk of death or serious adverse events. Overall, these findings highlight the importance of managing hyperuricemia and utilizing urate-lowering therapy to mitigate the adverse cardiovascular effects associated with elevated uric acid levels. |
| first_indexed | 2024-04-24T19:44:32Z |
| format | Article |
| id | doaj.art-c74156d40fd4490fb01e3b19408e9bf3 |
| institution | Directory Open Access Journal |
| issn | 1179-5468 |
| language | English |
| last_indexed | 2024-04-24T19:44:32Z |
| publishDate | 2024-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Cardiology |
| spelling | doaj.art-c74156d40fd4490fb01e3b19408e9bf32024-03-25T10:03:23ZengSAGE PublishingClinical Medicine Insights: Cardiology1179-54682024-03-011810.1177/11795468241239542Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular DiseasesFranklin Sosa0Mohammed Shaban1Jose Lopez2Gustavo J. Duarte3Swati Jain4Asma Khizar5Timothy Vittorio6Rishabh Mishra7Miguel Rodriguez Guerra8BronxCare Health System, Icahn School of Medicine, Bronx, NY, USABronxCare Health System, Icahn School of Medicine, Bronx, NY, USADivision of Cardiovascular Disease, University of Miami Miller School of Medicine/JFK Hospital, Atlantis, FL, USADivision of Cardiology, Cleveland Clinic Florida, Fort Lauderdale, FL, USAMontefiore Medical Center, Einstein College of Medicine, Bronx, NY, USAMontefiore Medical Center, Einstein College of Medicine, Bronx, NY, USABronxCare Health System, Icahn School of Medicine, Bronx, NY, USAMontefiore Medical Center, Einstein College of Medicine, Bronx, NY, USAMontefiore Medical Center, Einstein College of Medicine, Bronx, NY, USAThe association between hyperuricemia and cardiovascular diseases has been studied for many years. Research has shown a link between high uric acid levels and increased risk of including coronary artery disease hypertension and other cardiovascular conditions. Urate-lowering therapy, particularly with xanthine oxidase inhibitors like allopurinol, has shown promising results in reducing blood pressure in individuals with hyperuricemia and hypertension. Clinical trials and studies have demonstrated significant reductions in both systolic and diastolic blood pressure with urate-lowering treatment. Urate-lowering treatment has shown a favorable effect on reducing systolic blood pressure and major adverse cardiovascular events in patients with previous cardiovascular disease. In terms of cardiovascular safety, clinical trials have indicated that xanthine oxidase inhibitors such as febuxostat are non-inferior to allopurinol and do not increase the risk of death or serious adverse events. Overall, these findings highlight the importance of managing hyperuricemia and utilizing urate-lowering therapy to mitigate the adverse cardiovascular effects associated with elevated uric acid levels.https://doi.org/10.1177/11795468241239542 |
| spellingShingle | Franklin Sosa Mohammed Shaban Jose Lopez Gustavo J. Duarte Swati Jain Asma Khizar Timothy Vittorio Rishabh Mishra Miguel Rodriguez Guerra Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases Clinical Medicine Insights: Cardiology |
| title | Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases |
| title_full | Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases |
| title_fullStr | Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases |
| title_full_unstemmed | Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases |
| title_short | Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases |
| title_sort | impact of hyperuricemia and urate lowering agents on cardiovascular diseases |
| url | https://doi.org/10.1177/11795468241239542 |
| work_keys_str_mv | AT franklinsosa impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases AT mohammedshaban impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases AT joselopez impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases AT gustavojduarte impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases AT swatijain impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases AT asmakhizar impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases AT timothyvittorio impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases AT rishabhmishra impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases AT miguelrodriguezguerra impactofhyperuricemiaandurateloweringagentsoncardiovasculardiseases |